SCHEMBL7052538

SCHEMBL7052538

CCCCc1ncc(/C=C(\Cc2cccs2)c2nnn[nH]2)n1Cc1ccc(C(=O)O)cc1

nearest known ligand 0.76

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 4/20 0.71
ABCC3 O15438 1/20 0.71
ABCC2 Q92887 1/20 0.71
AGTR2 P50052 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7052541 1.00 AGTR1 (0.71) AGTR1ABCC3ABCC2AGTR2
SCHEMBL7052549 1.00 AGTR1 (0.71) AGTR1ABCC3ABCC2AGTR2
SCHEMBL9367466 0.91 AGTR1 (0.60) AGTR1ABCC3ABCC2
SCHEMBL9367461 0.91 AGTR1 (0.60) AGTR1ABCC3ABCC2
SCHEMBL9367457 0.91 AGTR1 (0.60) AGTR1ABCC3ABCC2
SCHEMBL9367687 0.91 AGTR1 (0.57) AGTR1ABCC3ABCC2
SCHEMBL9367702 0.91 AGTR1 (0.57) AGTR1ABCC3ABCC2
SCHEMBL9367695 0.91 AGTR1 (0.57) AGTR1ABCC3ABCC2
SCHEMBL7054518 0.89 AGTR1 (0.55) AGTR1ABCC3ABCC2
SCHEMBL7054525 0.89 AGTR1 (0.55) AGTR1ABCC3ABCC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030187044-A1 Medicament SMITHKLINE BEECHAM P.L.C. 2003-10-02 US claimed
US-20030096851-A1 Medicament SMITHKLINE BEECHAM P.L.C. 2003-05-22 US claimed
US-20030069293-A1 Medicament SMITHKLINE BEECHAM PLC 2003-04-10 US claimed
US-20030050285-A1 Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke SMITHKLINE BEECHAM P.L.C. 2003-03-13 US claimed
US-20030004201-A1 Medicament SMITHKLINE BEECHAM P.L.C. 2003-01-02 US claimed
US-20020160985-A1 Medicament SMITHKLINE BEECHAM PLC 2002-10-31 US claimed
US-20020132840-A1 Treating angina in a mammal by administering an angiotensin II receptor antagonist. SMITHKLINE BEECHAM P.1.C. 2002-09-19 US claimed
US-20020128300-A1 Treating diabetic retinopathy in a mammal by administering an angiotensin II receptor antagonist. SMITHKLINE BEECHAM P.L.C. 2002-09-12 US claimed
US-20020086893-A1 Imidazole based angiotensin II receptor antagonist for treating haemorrhagic stroke SMITHKLINE BEECHAM P.L.C. 2002-07-04 US claimed
US-20020068759-A1 Medicament SMITHKLINE BEECHAM PLC 2002-06-06 US claimed
WO-1992010184-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF ATHEROMA SMITHKLINE BEECHAM PLC (GB) 1992-06-25 WO claimed
WO-1992010186-A1 USE OF ANGIOTENSN II RECEPTOR ANTAGONISTS FOR THE PREPARATION OF A MEDICAMENT FOR IMPROVING COGNITIVE FUNCTION SMITHKLINE BEECHAM PLC (GB) 1992-06-25 WO claimed
WO-1992010183-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC RETINOPATHY SMITHKLINE BEECHAM PLC (GB) 1992-06-25 WO claimed
WO-1992010185-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE PREVENTION OF RESTINOSIS SMITHKLINE BEECHAM PLC (GB) 1992-06-25 WO claimed
WO-1992010180-A1 USE OF ANGIOTENSIN II ANTAGONIST IN THE TREATMENT OF INFARCTION SMITHKLINE BEECHAM PLC (GB) 1992-06-25 WO claimed
WO-1992010188-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF HEMORRAGIC STROKE SMITHKLINE BEECHAM PLC (GB) 1992-06-25 WO claimed
WO-1992010179-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF MACULAR DEGENERATION SMITHKLINE BEECHAM PLC (GB) 1992-06-25 WO claimed
WO-1992010182-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC NEPHROPATHY SMITHKLINE BEECHAM PLC (GB) 1992-06-25 WO claimed
WO-1992010187-A1 USE OF ANGIOTENSIN II ANTAGONISTS IN THE TREATMENT OF ANGINA PECTORIS SMITHKLINE BEECHAM PLC (GB) 1992-06-25 WO claimed
WO-1992010181-A1 USE OF ANGIOTENSIN II ANTAGONISTS IN THE TREATMENT OF LEFT VENTRICULAR HYPERTROPHY SMITHKLINE BEECHAM PLC (GB) 1992-06-25 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020160985-A1 Medicament AGTR2, AGTR1, ACE AGTR1 2/4885ABCC3 808/4885ABCC2 577/4885
US-20020132840-A1 Treating angina in a mammal by administering an angiotensin II receptor antagonist. AGTR2, AGTR1, AGT AGTR1 2/4885ABCC3 1102/4885ABCC2 523/4885
US-20030187044-A1 Medicament AGTR2, AGTR1, ACE AGTR1 2/4885ABCC3 2090/4885ABCC2 1339/4885
US-20020086893-A1 Imidazole based angiotensin II receptor antagonist for treating haemorrhagic stroke AGTR2, AGTR1, VIPR2 AGTR1 2/4885ABCC3 3754/4885ABCC2 2325/4885
US-20030004201-A1 Medicament AGTR2, AGTR1, ACE AGTR1 2/4885ABCC3 860/4885ABCC2 900/4885
US-20020068759-A1 Medicament AGTR2, AGTR1, ACE AGTR1 2/4885ABCC3 808/4885ABCC2 577/4885
US-20030096851-A1 Medicament AGTR2, AGTR1, ACE AGTR1 2/4885ABCC3 2090/4885ABCC2 1339/4885
US-20030050285-A1 Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke AGTR2, AGTR1, ACE AGTR1 2/4885ABCC3 3372/4885ABCC2 2275/4885
US-20030069293-A1 Medicament AGTR2, AGTR1, ACE AGTR1 2/4885ABCC3 808/4885ABCC2 577/4885
US-20020128300-A1 Treating diabetic retinopathy in a mammal by administering an angiotensin II receptor antagonist. AGTR2, AGTR1, REN AGTR1 2/4885ABCC3 1592/4885ABCC2 971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.